PARP inhibitor (PARPi) has been proven to cause DNA damage via catalytic inhibition of the PARP enzyme and trapping of DNA-PARP complexes, which results in synthetic lethality in cells deficient in homologous recombination repair, and consequently strengthen the use of killing tumor cells (7, 8). Here, PARP1 is linked to neoplasm.